Savant Capital LLC Sells 2,184 Shares of Hologic, Inc. (NASDAQ:HOLX)

Savant Capital LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,519 shares of the medical equipment provider’s stock after selling 2,184 shares during the period. Savant Capital LLC’s holdings in Hologic were worth $1,407,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HOLX. Wolff Wiese Magana LLC purchased a new stake in Hologic during the third quarter worth about $25,000. General Partner Inc. purchased a new stake in shares of Hologic during the 4th quarter worth approximately $26,000. First Horizon Advisors Inc. increased its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Cromwell Holdings LLC raised its holdings in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the period. Finally, Covestor Ltd lifted its stake in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 133 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.1 %

Hologic stock opened at $63.62 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49. Hologic, Inc. has a fifty-two week low of $63.39 and a fifty-two week high of $84.67. The stock has a market cap of $14.36 billion, a P/E ratio of 20.07, a PEG ratio of 2.14 and a beta of 0.97. The firm’s fifty day moving average price is $71.28 and its 200-day moving average price is $77.37.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Jefferies Financial Group assumed coverage on Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price for the company. UBS Group boosted their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Morgan Stanley dropped their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Wolfe Research began coverage on shares of Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Finally, Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.77.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is currently owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.